Vaccines for blocking transmission of plasmodium vivax

Details Vaccines for blocking transmission of plasmodium vivax Vaccines for blocking transmission of plasmodium vivax

2006-12-15

2008-08-05

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S272100

Reexamination Certificate

active

07407658

ABSTRACT:
The present invention relates novel methods and compositions for blocking transmission ofPlasmodium vivaxwhich cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface ofPlasmodium vivaxzygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.

REFERENCES:
patent: WO 89/10936 (1989-11-01), None
patent: WO 94/01552 (1994-01-01), None
patent: WO 94/28930 (1994-12-01), None
patent: WO 95/08631 (1995-03-01), None
patent: WO 98/14472 (1998-04-01), None
Duffy et al, A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines, 1997, Infect Immun, vol. 65:1109-13.
Kaslow et al, Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA Agarose. 1994, Natur Biotechnology, vol. 12:494-9.
Miller et al, New gene for 25 kDa surface antigen of plasmodium falciparum—in sexual development stages, useful in transmission-blocking malaria vaccine. 1990, SCORE result.
Hisaeda, H., et al., “Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect Mosquitoes,”Infection and Immunity, vol. 68, No. 12, pp. 6618-6603 (Dec. 2000).
Kofta, W., et al., “c-DNA vaccination against parasitic infections: advantages and disadvantages,”Veterinary Parasitology, vol. 100, pp. 3-12 (2001).
Kongkasuriyachai, D., et al., “Potent immunogenicity of DNA vaccines encodingPlasmodium vivaxtransmission-blocking vaccine candidates Pvs25 and Pvs28—evaluation of homologous and heterologous antigen-delivery prime-boost strategy,”Vaccine, vol. 22, pp. 3205-3213 (2004).
McCluskie, M., et al., “Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates,” Molecular Medicine, vol. 5, pp. 287-300 (1999).
Mendis, K. et al., “Immune modulation of parasite transmission inPlasmodium vivaxmalaria: Anti-gamete antibodies can both block and enhance transmission”;Molecular Strategies of Parasitic Invasion; pp. 417-426, 1987. Alan R. Liss, Inc.
Premawansa, S. et al., “Target antigens of transmission blocking immunity ofPlasmodium vivaxmalaria: Characterization and polymorphism in natural parasite isolates”;J. Immunol. vol. 144 (11), pp. 4376-4383 (Jun. 1, 1990).
Snewin, V. et al., “Transmission blocking immunity inPlasmodium vivaxmalaria: Antibodies raised against a peptide block parasite development in the mosquito vector”;J. Exp. Med., vol. 181, pp. 357-362 (Jan. 1995).
Tsuboi, T., et al., “Sequence Polymorphism in Two NovelPlasmodium vivaxOokinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine Candidates,”Molecular Medicine, vol. 4, pp. 772-782 (1998).

Affiliated with

Also associated with

Rating

Vaccines for blocking transmission of plasmodium vivax does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines for blocking transmission of plasmodium vivax, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines for blocking transmission of plasmodium vivax will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4008722